

Applicant : Nai-Kong CHEUNG
U.S. Serial No.: 10/621,027
Filed : July 16, 2003
Page : 2

AMENDMENTS TO THE CLAIMS:

Please cancel claims 67-119 without prejudice to the Applicant's rights to pursue the subject matters in a future application:

1-119. (Canceled)

120. (New) A composition comprising a glucan, wherein the glucan is administered by oral route, in an amount wherein the glucan and an antibody administered to a subject have synergistic effect.

121. (New) The composition of claim 120, wherein the antibody is a monoclonal antibody.

122. (New) The composition of claim 120, wherein the antibody is an antibody against cancer.

123. (New) The composition of claim 122, wherein the antibody is a tumor-binding antibody.

124. (New) The composition of claim 123, wherein the antibody is capable of activating complement.

125. (New) The composition of claim 124, the antibody is further capable of activating the antibody dependent cell-mediated cytotoxicity.

126. (New) The composition of claim 123, wherein the antibody is directed at HER-1 (epidermal growth factor receptor).

127. (New) The composition of claim 123, wherein the antibody is directed to a ganglioside.

Applicant : Nai-Kong CHEUNG
U.S. Serial No.: 10/621,027
Filed : July 16, 2003
Page : 3

128. (New) The composition of claim 127, wherein the ganglioside is GD2 or GD3.
129. (New) The composition of claim 123, wherein the antigen is CD20 or CD22.
130. (New) The composition of claim 123, wherein the antigen is HER-2/neu.
131. (New) The composition of claim 123, wherein the antigen is CD25.
132. (New) The composition of claim 122, wherein the cancer is neuroblastoma, melanoma, non-Hodgkin's lymphoma, Epstein-Barr related lymphoma, Hodgkin's lymphoma, retinoblastoma, small cell lung cancer, brain tumors, leukemia, epidermoid carcinoma, prostate cancer, renal cell carcinoma, transitional cell carcinoma, breast cancer, ovarian cancer, lung cancer, colon cancer, liver cancer, stomach cancer, or other gastrointestinal cancers.
133. (New) The composition of claim 120 and a pharmaceutically acceptable carrier.
134. (New) The composition of claim 120, wherein the glucan comprises 1,3- β and 1,4- β -linkages in the backbone.
135. (New) The composition of claim 120, wherein the glucan is of high molecular weight.
136. (New) The composition of claim 135, wherein the molecular weight of the glucan ranges from 250,000 to 450,000 Daltons.

Applicant : Nai-Kong CHEUNG
U.S. Serial No.: 10/621,027
Filed : July 16, 2003
Page : 4

137. (New) The composition of claim 120, wherein the glucan is derived from barley, oat, wheat, moss or yeast.
138. (New) The composition of claim 120, wherein the glucan is stable to heat treatment.
139. (New) The composition of claim 138, wherein the composition is stable after boiling for 3 hours.
140. (New) The composition of claim 120, wherein the glucan further comprises 1,6- β side chain.
141. (New) The composition of claim 134, wherein the glucan further comprises 1,6- β side chain.
142. (New) The composition of claim 120, wherein the effective dose is about ≥ 25 mg/kg/day, five days a week for a total of 2-4 weeks.
143. (New) The composition of claim 134, wherein the effective dose is about ≥ 25 mg/kg/day, five days a week for a total of 2-4 weeks.
144. (New) The composition of claim 140, wherein the effective dose is about ≥ 25 mg/kg/day, five days a week for a total of 2-4 weeks.
145. (New) The composition of claim 141, wherein the effective dose is about ≥ 25 mg/kg/day, five days a week for a total of 2-4 weeks.

Applicant : Nai-Kong CHEUNG
U.S. Serial No.: 10/621,027
Filed : July 16, 2003
Page : 5

146. (New) The composition of claim 120, wherein the glucan and the antibody are administered concurrently.
147. (New) A composition comprising an effective amount of glucan, wherein the glucan is administered by oral route, and wherein the effective amount is an amount where the glucan and an antibody administered to a subject have synergistic effect, wherein the glucan comprises 1,3- β and 1,4- β -linkages in the backbone.
148. (New) A composition comprising an effective amount of glucan, wherein the glucan is administered by oral route, and wherein the effective amount is an amount where the glucan and an antibody administered to a subject have synergistic effect, wherein the glucan comprises 1,6- β side chain.